Eli Lilly LLC - Search News

Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake

The price a stock trades at can drastically impact your overall returns. If you wait for a top growth stock to come down to a P/E of 20 or less, you may end up waiting forever and missing out on the opportunity completely.

Hosted on MSN · 20h

Lilly Endowment sells $31.18 million in Eli Lilly stock

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion of its holdings in the pharmaceutical giant. According to a recent SEC filing,

MarketWatch · 20h

Eli Lilly & Co. stock underperforms Friday when compared to competitors

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.37% to 44,546.08.

4don MSN

Eli Lilly announces $6.5 billion six-part note offering

Eli Lilly (NYSE:LLY) has filed for a six-part note offering, with the aggregate principal amount of the notes offered ...

Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals

Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...

Yahoo Finance8d

Q4 2024 Eli Lilly and Co Earnings Call

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel ...

ABC News9d

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

MarketWatch8d

Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results